The variable “reduced metabolism of quetiapine”—determined by the presence of CYP3A4*22 allele—was identified as a significant predictor of lower scores in the overall CGI-BP-M (p-value < 0.038) and the depression subdomain (p-value < 0.025) at enrollment. Here, CYP3A4 is linked to depressive disorder.